[Long-term results of antiandrogenous therapy of prostate cancer]

The results of observation of 135 patents with prostate cancer who underwent bilateral subcapsular orchiectomy at the period from 1998 to 2010 allowed generalization of 5- and 10- year survival of the patients which was (67.84 +/- 4.05)% and (48.4 +/- 5.4)% corrected as (80.54 +/- 3.5)% and (69.28 +/- 6.22)% respectively. Criteria of prognosis of outcomes of antiandrogenous therapy were worked out by the results of multifactor analysis. The overall 5- and 10- year survival in the group of patients of low risk of lethal outcome was 90.21 and 72.81%, intermediate risk--71.80% and 52.11% and in the group of high risk 35.29 and 12.83% corrected as 98.08 and 98.08%; 94.20 and 81.32%; 38.02 and 20.01% respectively. The most significant factors influencing the duration of the patients' life were the stage of the disease, degree of cellular differentiation, age of the patient.